(Press-News.org) Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm.
"This is a major step forward in prostate cancer therapeutics," said Dr Johann de Bono from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in London, who presented the study results at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. "Patients in this Phase-III trial who received abiraterone had a median survival of four months longer than patients receiving a placebo."
"These results are likely to alter the standard of care for men with advanced prostate cancer who have progressed despite receiving docetaxel-based chemotherapy, a critically important area of unmet need," Dr de Bono said. "Men with metastatic castration-resistant prostate cancer have a poor prognosis, with only about one in three alive five years after diagnosis. For many men, abiraterone acetate can extend life."
Because the growth of prostate cancer is fuelled by the male hormone testosterone, reduction of the testosterone level in the body --for example through hormone therapy--can slow the tumor growth. But most prostate cancers eventually become resistant to these treatments and resume growing.
Abiraterone acetate is designed to treat these tumors by inhibiting the production of androgen in the testes, the adrenal glands and prostate cancer tumors themselves. The Phase-III trial included 1195 patients from 13 countries whose metastatic, castration-resistant prostate cancer had previously been treated with one of two chemotherapeutic agents that included docetaxel.
Among the 398 patients randomly assigned to receive the corticosteroid prednisone plus placebo, median overall survival was 10.9 months. Among the 797 who received abiraterone acetate plus prednisone, median survival was 14.8 months.
Significant differences also emerged between the placebo and treatment groups for all of the trial's secondary endpoints, including time to prostate-specific antigen (PSA) progression, radiographic progression-free survival and PSA response rate.
The benefits of abiraterone were determined during a pre-specified interim analysis of the study, prompting the trial's Independent Data Monitoring Committee to recommend unblinding the trial, and allowing anyone on the placebo arm to be offered abiraterone acetate.
"Once we knew that the drug could prolong life for many patients, it was ethically critical that we made it available to all patients on the trial," Dr de Bono said.
The researcher noted that there were still some unanswered questions about abiraterone.
"A key question now is how to work out which patients will benefit from the drug --clearly, some patients do and some don't. So although this is a significant advance, there is still a lot of work to do to improve outcomes for advanced prostate cancer."
Professor Carsten Bokemeyer, director of University Cancer Center Hamburg, Germany, commented that abiraterone acetate "is a true additional new treatment in prostate cancer."
"The results of this study show that the drug adds to the range of treatment options available for patients with advanced disease, with limited toxicity," Prof Bokemeyer said. "These results also challenge the current idea that there is no further treatment after chemotherapy for these patients. In fact, timing of hormone therapy and chemotherapy will become more complex and important in the future management of castration-resistant prostate cancer."
INFORMATION: END
Many cancer survivors experience changes in sexual function that leave them feeling guilty and a longing for intimacy, Australian researchers told at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The researchers say that these sexuality and fertility concerns are often not adequately addressed by doctors.
Professor Bogda Koczwara from Flinders Medical Centre in Adelaide said that fertility concerns among cancer survivors was a growing problem, due to a combination of improved cancer treatment outcomes in young cancer survivors ...
In life, we're told, we must take the good with the bad, and how we view these life events determines our well-being and ability to adjust. But according to Prof. Dov Shmotkin of Tel Aviv University's Department of Psychology, you need more than the right attitude to successfully negotiate the vicissitudes of life.
As recently reported in Aging and Mental Health, Prof. Shmotkin's research reveals that people's well-being and their adaptation can be ascertained by their "time trajectory" ― their concept of how they have evolved through their remembered past, currently ...
New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient's sex life, researchers have found.
At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, French researchers reported on one of the few studies to investigate the impact of cancer therapy on the sexual functioning of patients.
Dr Yohann Loriot and Dr Thomas Bessede from Institut Gustave Roussy in Villejuif, France and colleagues found that patients taking ...
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Vincent Miller from Memorial Sloan-Kettering Cancer Center in New York, USA, reported findings from the LUX-Lung 1 trial of afatinib in 585 patients with lung adenocarcinoma whose cancer had progressed after chemotherapy ...
A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO).
Preliminary results from an ongoing Phase-II trial of the drug PF299804 (PF-299) showed that close to 85% of patients whose cancers harbor mutated forms of the EGFR gene have remained progression-free for at least nine months, reported Dr Tony Mok from the Chinese University of Hong Kong.
While some ...
An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
Urothelial cancers affect the tissue lining the inner surfaces of the bladder and other parts of the urinary system. In cases of metastatic disease, median survival is approximately 12-15 months and there is a 10-15% chance of prolonging it by the use of standard chemotherapy regimens, particularly in otherwise healthy ...
The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.
At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Marianne Pavel from Charité University in Berlin, Germany reported that everolimus improved progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors.
Neuroendocrine tumors are slow-growing malignancies that originate from cells of the body's neuroendocrine ...
A new class of compounds identified by researchers at Emory University School of Medicine could be developed into drugs for the treatment of schizophrenia. The compounds enhance signaling by molecules in the brain called NMDA receptors, which scientists believe are functioning at low levels in people with schizophrenia.
Led by Stephen Traynelis, PhD, professor of pharmacology, a team of Emory researchers sifted through thousands of chemicals and found one, called CIQ, which could selectively enhance the function of certain NMDA receptors without affecting others.
The ...
Iowa City, IA—October 11, 2010— A new study published in Applied Cognitive Psychology finds that college-aged men are very likely to remember a woman's initial sexual interest (attraction or rejection), especially when the woman in question is thought to be attractive, is dressed more provocatively, and expresses positive sexual interest.
In the study the men were shown full-body photographs of college-aged women who expressed cues of sexual interest or rejection. The participating males represented mixed sexual histories, and a capacity for varying degrees of sexually ...
GAINESVILLE, Fla. --- University of Florida researchers presenting new fossil evidence of an exceptionally well-preserved 55-million-year-old North American mammal have found it shares a common ancestor with rodents and primates, including humans.The study published today in the online edition of the Zoological Journal of the Linnean Society, describes the cranial anatomy of the extinct mammal, Labidolemur kayi.
High resolution CT scans of the specimens allowed researchers to study minute details in the skull, including bone structures smaller than one-tenth of a millimeter. ...
